Clinical Trial Update: Pharmacokinetics of Oral Hydroxyurea Solution [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 pharmacokinetics study of an oral hydroxyurea solution in sickle cell disease and related hemoglobin disorders, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemoglobin Sc Disease
• Sickle Cell Disease
• Sickle Cell-beta-thalassemia
• Thalassemia

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Nova Laboratories Limited | Conditions: Sickle Cell Disease, Sickle-Cell; Hemoglobin Disease, Thalassemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-28